Ontology highlight
ABSTRACT: Background
Huntington's disease (HD) is an inherited, progressive neurodegenerative disease that has no cure. Striatal atrophy and hypometabolism has been described in HD as far as 15 years before clinical onset and therefore structural and functional imaging biomarkers are the most applied biomarker modalities which call for these to be exact; however, most studies are not considering the partial volume effect and thereby tend to overestimate metabolic reductions, which may bias imaging outcome measures of interventions.Objective
Evaluation of partial volume effects in a cohort of premanifest HD gene-expansion carriers (HDGECs).Methods
21 HDGECs and 17 controls had a hybrid 2-[18F]FDG PET/MRI scan performed. Volume measurements and striatal metabolism, both correct
SUBMITTER: Hellem MNN
PROVIDER: S-EPMC8195345 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature